Supernus Pharmaceuticals Files 8-K on Financials
Ticker: SUPN · Form: 8-K · Filed: Jul 23, 2024 · CIK: 1356576
| Field | Detail |
|---|---|
| Company | Supernus Pharmaceuticals, Inc. (SUPN) |
| Form Type | 8-K |
| Filed Date | Jul 23, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: SUPN
TL;DR
SUPN filed an 8-K with financial results on 7/23/24.
AI Summary
On July 23, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements and exhibits related to the company's performance.
Why It Matters
This filing provides investors with updated financial information and operational details for Supernus Pharmaceuticals, Inc., crucial for assessing the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — Registrant
- July 23, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Rockville, MD (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by Supernus Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is July 23, 2024.
In which state was Supernus Pharmaceuticals, Inc. incorporated?
Supernus Pharmaceuticals, Inc. was incorporated in Delaware.
What is the address of Supernus Pharmaceuticals, Inc.'s Principal Executive Offices?
The address of Supernus Pharmaceuticals, Inc.'s Principal Executive Offices is 9715 Key West Ave, Rockville, MD 20850.
What is the SEC file number for Supernus Pharmaceuticals, Inc.?
The SEC file number for Supernus Pharmaceuticals, Inc. is 001-35518.
Filing Stats: 490 words · 2 min read · ~2 pages · Grade level 9.2 · Accepted 2024-07-23 16:20:54
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Sto
Filing Documents
- supn-20240723.htm (8-K) — 27KB
- ex99107-23x2024.htm (EX-99.1) — 9KB
- image_0.jpg (GRAPHIC) — 5KB
- 0001356576-24-000039.txt ( ) — 165KB
- supn-20240723.xsd (EX-101.SCH) — 2KB
- supn-20240723_lab.xml (EX-101.LAB) — 21KB
- supn-20240723_pre.xml (EX-101.PRE) — 12KB
- supn-20240723_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On July 23, 2024, Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report its business results for the second quarter 2024 after the market closes on Tuesday, August 6, 2024. The Company will host a conference call and webcast on Tuesday, August 6, 2024 at 4:30 p.m. E.T. to discuss its second quarter 2024 business and financial results. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release dated July 23, 2024 filed as an Exhibit pursuant to Item 2.02 hereof. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SUPERNUS PHARMACEUTICALS, INC. DATED: July 23, 2024 By: /s/ Timothy C. Dec Timothy C. Dec Senior Vice President and Chief Financial Officer 3